The FDA now requires a boxed warning for montelukast (Singulair) due to the risk of neuropsychiatric events associated with the drug. The FDA said Wednesday it will now require a boxed warning—the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback